Position in JANX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$58,436,828
+$9,091,828 QoQ
Shares Held
3,804,481
+7.2% QoQ
Ownership
6.22%
of shares outstanding
% of Portfolio
10.07%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Prosight Management, LP holds $415,390,745 across 22 Biotechnology names. JANX ranks #2 (14.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LKFT |
Lakefront Biotherapeutics NV
|
2,043,344 | $61,259,453 | |
| 2 | JANX |
Janux Therapeutics, Inc.
This page
|
3,804,481 | $58,436,828 | |
| 3 | NKTR |
Nektar Therapeutics
|
810,000 | $56,546,100 | |
| 4 | STTK |
Shattuck Labs, Inc.
|
5,957,877 | $41,347,666 | |
| 5 | INSM |
INSMED Inc
|
375,609 | $40,047,431 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
98,080 | $29,525,022 | |
| 7 | SNDX |
Syndax Pharmaceuticals Inc
|
1,200,000 | $26,232,000 | |
| 8 | KURA |
Kura Oncology, Inc.
|
2,021,964 | $22,180,945 |
All Filings in JANX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $58,436,828 | 3,804,481 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $49,345,000 | 3,550,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $33,016,817 | 2,392,523 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $21,149,154 | 865,350 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $19,725,182 | 853,904 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $18,627,327 | 689,901 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $17,655,778 | 329,768 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $9,313,150 | 205,000 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||